Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.

CMS' 340B Reform Effort Shakes Up Hospital-Clinic Partnerships

March 29th 2019

Following a multiyear trend in which oncology practices merged with hospitals to achieve savings and improved care, it appeared as though the pendulum was going to swing the other way.

Emerging Approaches for BRAF-Mutant Metastatic Melanoma

March 28th 2019

Treatment Sequencing in BRAF+ Metastatic Melanoma

March 28th 2019

Treatment Adherence and Response With BRAF-Targeted Therapy

March 28th 2019

BRAF/MEK Frontline Therapy in Metastatic Melanoma

March 28th 2019

Maximizing BRAF/MEK Inhibition in Melanoma

March 28th 2019

Recommendations for Managing BRAF+ Metastatic Melanoma

March 28th 2019

BRAF-Targeted Therapy in Melanoma: Toxicity Management

March 28th 2019

Treating Melanoma Patients With BRAF/MEK Dual-Targeted Therapy

March 28th 2019

The COLUMBUS Trial in BRAF-Mutant Melanoma

March 28th 2019

BRAF/MEK Combinations Available in Advanced Melanoma

March 28th 2019

BRAF/MEK Dual-Targeted Therapy in Advanced Melanoma

March 28th 2019

Addressing Challenges With BRAF Inhibitors in Melanoma

March 28th 2019

BRAF as a Driver in Melanoma

March 28th 2019

Melanoma as an Oncogene-Addicted Cancer

March 28th 2019

Gene Mutations in Melanoma

March 28th 2019

FDA Proposes Policy Changes to Improve Mammography Quality Standards

March 28th 2019

The FDA has proposed amendments to key policies to modernize breast cancer screening and improve mammography services, in order to enable healthcare providers and patients to make more informed medical decisions

US Market Is Still Waiting for Biosimilars to Produce Meaningful Price Reductions

March 14th 2019

When the FDA approved its first biosimilar drug in 2015—filgrastim-sndz, for compromised white blood cell count—there was talk of the benefits of competition in the pharma industry; increased access to medications for patients; and, of course, the all-around savings. Four years later, those benefits haven’t been fully realized,

NCI Director Ned Sharpless to Be Named Acting FDA Commissioner

March 13th 2019

National Cancer Institute director Norman (Ned) E. Sharpless, MD, has been named as acting commissioner of the FDA once Scott Gottlieb, MD, leaves the regulatory agency in April 2019.

NCCN Guidelines Gain Traction Around the Globe

March 4th 2019

Global use of cancer management guidelines from the National Comprehensive Cancer Network has climbed rapidly in recent years.